Shanghai Pharmaceuticals 2025 Annual Report: Key Insights for Investors

1. Financial Performance & Dividend Distribution

• Operating Income: The Group reported operating income of RMB 283.58 billion for 2025, a YoY increase of 3.03%. The rise was primarily driven by increased sales revenue.
• Net Profit: Profit attributable to shareholders reached RMB 5.72 billion, up 25.8% from 2024 (RMB 4.55 billion). Basic and diluted EPS were both RMB 1.54, compared to RMB 1.23 in 2024, representing robust growth.
• Total Comprehensive Income: The total comprehensive income attributable to shareholders stood at RMB 5.73 billion.
• Dividend Proposal: The Board is recommending a cash dividend of RMB 3.50 per 10 shares (tax inclusive), totaling RMB 1.30 billion for the year-end. Including the interim dividend, the total dividend payout for 2025 is RMB 1.74 billion, representing 30.45% of consolidated net profit attributable to shareholders. The dividend policy remains stable, with cumulative three-year cash dividends exceeding 30% of average annual distributable profit.
• Reserve Fund Available for Distribution: The company has RMB 2.92 billion in distributable reserves as of 31 December 2025, ensuring ample room for future dividend payments.

2. Strategic and Operational Highlights

• Fortune Global 500 Ranking: Shanghai Pharmaceuticals was ranked 407th in the 2025 Fortune Global 500, reinforcing its industry leadership.
• International Expansion: The company made significant headway in Southeast Asia and the Middle East:
  • 11 products (16 specifications) were approved overseas in 2025.
  • 18 new overseas project registrations were completed, and 32 projects are under review.
  • SPH Thailand saw sales surge by 250.1% YoY, while SPH Philippines recorded its first sales revenue, marking a business breakthrough.
• Innovation and R&D:
  • Stogilan Malate Tablets (class 1 innovative drug) was approved for marketing, targeting over 300 million primary hypertension patients in China.
  • B001 Injection, a globally innovative anti-CD20 drug, advanced clinical studies.
  • Total R&D investment for 2025 was RMB 2.60 billion (10.62% of operating income), with 1,817 R&D personnel (3.66% of staff).
  • Shanghai Pharmaceuticals acquired an additional 10% equity in Shanghai Hutchison Pharmaceuticals, increasing its stake to 60% and thus consolidating the subsidiary’s results into the Group’s accounts. This change contributed significantly to investment income (RMB 3.17 billion, up 733.3% YoY).
• Digital Transformation: The company advanced digital intelligence and AI integration, issuing guidelines and implementing AI-driven operational improvements.

3. Risk Factors and Challenges

• Geopolitical and Economic Risks: International trade, investment, and raw material imports face short-term fluctuations due to macroeconomic and geopolitical uncertainties.
• Medical Insurance Reforms: Ongoing cost control and payment reforms in China’s medical insurance system may lead to further price reductions for certain drugs, potentially impacting margins.
• Innovation Risks: R&D projects have long lead times and face approval uncertainties. The company is mitigating this with increased R&D investment and resource optimization.
• Goodwill Impairment: Goodwill is subject to impairment risk, dependent on management’s future cash flow forecasts and market assumptions.
• Credit Impairment: The company increased provisions for asset and credit impairment, reflecting stricter risk management amid a challenging environment.

4. Capital Structure, Liquidity & Financial Position

• Cash Flow: Operating cash flow increased 5.61% to RMB 6.15 billion, while net cash from investing and financing activities saw substantial outflows due to increased investment in financial assets and lower short-term financing.
• Gearing Ratio: The Group’s gearing ratio rose to 24.37% in 2025 from 21.40% in 2024, indicating higher leverage but within a manageable range.
• Commitments: Capital expenditure commitments at year-end were RMB 1.71 billion, notably down from RMB 2.40 billion in 2024, suggesting a moderated investment pace.
• Liquidity Risks: The company holds substantial short-term and long-term borrowings, with the majority at floating rates. A 10% interest rate rise would reduce profit before tax by approximately RMB 6.25 million.

5. Major Shareholdings and Governance

• Top Shareholders:
  • HKSCC Nominees Limited holds 24.76% (918 million shares).
  • Shanghai Pharmaceutical (Group) holds 19.32% (717 million shares).
  • Yunnan Baiyao holds 17.95% (666 million shares).
  • SIIC International Investment owns 8.40% (312 million shares).
  • Other state-owned and institutional investors make up the rest.
• Share Options: 3.74 million A shares can be issued under the company’s option incentive schemes, representing a minimal dilution (0.13% of weighted average A shares).
• Public Float: The company satisfies both PRC and Hong Kong requirements, with over 10% of H shares held by the public.
• Corporate Governance: The company emphasizes compliance, risk management, and robust internal controls, with no material weaknesses identified. It also maintains regular communication with investors and upholds strong anti-bribery measures.

6. Notable Transactions and Events

• Connected Transactions: Continuing transactions with the Group’s Finance Company (deposit services) remained within approved annual caps and followed normal business terms, with proper governance and disclosure.
• Significant Asset/Liability Changes:
  • Intangible assets rose 55.65% to RMB 8.74 billion due to business combinations (notably consolidation of Hutchison Pharmaceuticals).
  • Derivative financial assets and bearer biological assets declined dramatically due to fair value movements and impairments.
  • Dividend payable surged 181.9% to RMB 1.07 billion, reflecting higher distributions.
• Pending Events:
  • The company plans to transfer its 30% equity in Sino-American Shanghai Squibb Pharmaceuticals Ltd. via public listing, which could impact future investment income and asset structure depending on deal terms.

7. Forward Guidance & Shareholder Considerations

• Growth Prospects: The company is poised for further growth through international expansion, innovation, and digital transformation, but faces ongoing challenges from regulatory reforms and global uncertainties.
• Dividend Stability: The company remains committed to stable and generous dividends, supporting long-term shareholder value.
• Potential Price Movers:
  • Further regulatory reforms, especially in drug pricing, or macroeconomic shocks could negatively impact earnings.
  • Major acquisitions or disposals (such as the planned transfer of the Squibb JV stake) may significantly affect reported results and capital structure.
  • Breakthroughs in R&D or successful overseas expansion could drive share price upside.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult a qualified financial advisor before making investment decisions. The information is based on Shanghai Pharmaceuticals Holding Co., Ltd.’s 2025 Annual Report and is subject to change. No liability is accepted for actions taken based on this article.

View SH PHARMA Historical chart here